Physician profile
Matthew G Smith
NPI 1235121724
$2,798.01
in general payments reported to CMS, 2019-2025
10 companies · $209 in 2025
The $209 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $779 · 2020: $136 · 2021: $553 · 2022: $625 · 2023: $377 · 2024: $118 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $691 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $690.70 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,071.08 | 2019-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $644.35 | 2019-2021 | |
| Abbott Laboratories | $284.32 | 2022-2025 | Triclip |
| Novo Nordisk INC | $274.82 | 2019-2022 | |
| Medtronic, INC. | $139.98 | 2022-2025 | Endurant Iis |
| Lilly USA, LLC | $133.09 | 2023 | Mounjaro, Trulicity, Jardiance |
| Amgen INC. | $118.88 | 2023-2024 | Evenity |
| Glaxosmithkline, LLC. | $105.10 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.45 | 2024 | Jardiance |
| Pfizer INC. | $12.94 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.